32° Sunny

Site search

Open user controls
- Log In Using Your Account
  Log In
  
  Don't have an account? Sign Up Today

- My Account
- Dashboard
- Profile
- Saved items
- Logout

Home
News
- Local News
- State News
Sports
- Local Sports
- Pro Sports
Lifestyle
- Local Entertainment
Multimedia
Community Choice
Features
Classifieds
- Place Ad
- Legal Notices
Public Notices
Obituaries
E-Edition

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

UroGen Pharma Ltd. - Ordinary Shares (NQ:URGN)

21.53 +1.32 (+6.53%)

Streaming Delayed Price Updated: 11:08 AM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about UroGen Pharma Ltd. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 Next >

Securities Fraud Investigation Into UroGen Pharma Ltd. (URGN) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

May 16, 2025

From The Law Offices of Frank R. Cruz

Via Business Wire

UroGen Pharma Reports First Quarter 2025 Financial Results and Provides a Business Update

May 12, 2025

From UroGen Pharma Ltd.

Via Business Wire

UroGen Announces FDA Advisory Committee for UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

May 07, 2025

From UroGen

Via Business Wire

UroGen Pharma to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

May 01, 2025

From UroGen Pharma Ltd.

Via Business Wire

OLYMPUS Long-Term Follow-Up Study Reports Nearly Four-Year Duration of Response in Subset of Patients with Low-Grade Upper Tract Urothelial Cancer Who Achieved a Complete Response to Initial JELMYTO Treatment

April 27, 2025

From UroGen Pharma Ltd.

Via Business Wire

New Patient-Reported Outcomes from UGN-102 Clinical Trials Show the Investigational Treatment Did Not Adversely Affect Functionality, Symptom Burden, and Quality of Life in Patients with LG-IR-NMIBC

April 27, 2025

From UroGen Pharma Ltd.

Via Business Wire

New Long-Term Follow-Up Data from OPTIMA II Study of UGN-102 Demonstrates Median Duration of Response of Two Years in Patients with LG-IR-NMIBC

April 27, 2025

From UroGen Pharma Ltd.

Via Business Wire

UroGen Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)

April 26, 2025

From UroGen Pharma Ltd.

Via Business Wire

UroGen Pharma Announces Encouraging Results from a Phase 1 Dose-Escalation Study Evaluating UGN-301 in Non-Muscle Invasive Bladder Cancer

April 26, 2025

From UroGen Pharma Ltd.

Via Business Wire

UroGen Announces Data Presentations at the American Urological Association 2025 Annual Meeting Highlighting Emerging Evidence Supporting Our Portfolio for Urothelial Cancers

April 14, 2025

From UroGen Pharma Ltd.

Via Business Wire

UroGen Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102

March 10, 2025

From UroGen Pharma Ltd.

Via Business Wire

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 07, 2025

From UroGen Pharma Ltd.

Via Business Wire

UroGen Pharma to Report Fourth Quarter and Full-Year 2024 Financial Results on Monday, March 10, 2025

February 27, 2025

From UroGen Pharma Ltd.

Via Business Wire

UroGen Pharma to Present at TD Cowen 45th Annual Health Care Conference

February 24, 2025

From UroGen Pharma Ltd.

Via Business Wire

UroGen Advances Long-Term Growth Strategy by Acquiring a Next-Generation Investigational Oncolytic Virus (ICVB-1042) and Announces Multiple Strategic Research Collaborations

February 20, 2025

From UroGen Pharma Ltd.

Via Business Wire

UroGen Pharma Ltd. (NASDAQ: URGN), CS Diagnostics Corp. (OTCQB: CSDX) and Boston Scientific (NYSE: BSX) Advancing Cancer Treatment Technology – More Stocks Inside

February 19, 2025

Via AB Newswire

UroGen Announces Results from Subgroup Analyses of the Pivotal ENVISION Trial Evaluating Impact of Baseline Tumor Burden and Focality on Response to UGN-102

February 14, 2025

From UroGen Pharma Ltd.

Via Business Wire

Data from a Long-Term Follow-up Study to the OLYMPUS Trial that Shows a Median Duration of Response of Nearly Four Years in Patients Achieving Complete Response with JELMYTO Published in The Journal of Urology

February 12, 2025

From UroGen Pharma Ltd.

Via Business Wire

UroGen Pharma to Present at Upcoming Investor Conferences

January 30, 2025

From UroGen Pharma Ltd.

Via Business Wire

New Real-World Durability of Response Data for JELMYTO Reports 68% Recurrence-Free Survival Rate (RFS) at Three Years Across a Broad Patient Population with Low-Grade Upper Tract Urothelial Cancer (LG-UTUC)

January 22, 2025

From UroGen Pharma Ltd.

Via Business Wire

ENVISION Trial Results Published in the February Issue of The Journal of Urology Highlight UGN-102 Achievement of 82.3% Duration of Response at 12 Months Paving the Way for the Potential First FDA-Approved Treatment for LG-IR-NMIBC in June 2025

January 15, 2025

From UroGen Pharma Ltd.

Via Business Wire

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 06, 2024

From UroGen Pharma Ltd.

Via Business Wire

Long-Term Follow-up Study to the OLYMPUS Trial Presented at SUO 2024 Reports Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO®

December 05, 2024

From UroGen Pharma Ltd.

Via Business Wire

UGN-102 Showed Promising Long-Term Results in the Phase 3 ENVISION Trial, Potentially Paving the Way for First FDA-Approved Treatment for LG-IR-NMIBC

December 05, 2024

From UroGen Pharma Ltd.

Via Business Wire

UroGen Announces New Data Presentations at the Society of Urologic Oncology 2024 Annual Meeting Highlighting Urothelial Cancer Portfolio Aimed at Addressing Unmet Needs

December 02, 2024

From UroGen Pharma Ltd.

Via Business Wire

New Data from a Long-Term Follow-up Study to the OLYMPUS Trial Show Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO®

November 26, 2024

From UroGen Pharma Ltd.

Via Business Wire

UroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025

November 06, 2024

From UroGen Pharma Ltd.

Via Business Wire

UroGen Pharma to Present at the Guggenheim Securities Healthcare Innovation Conference

November 05, 2024

From UroGen Pharma Ltd.

Via Business Wire

UroGen Pharma to Report Third Quarter Financial Results on Wednesday, November 6, 2024

October 30, 2024

From UroGen Pharma Ltd.

Via Business Wire

ENVISION Trial Results Published in the Journal of Urology Report 82.3% Duration of Response 12 Months after Achieving Complete Response for UGN-102, Potentially First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC

October 28, 2024

From UroGen Pharma Ltd.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

Home
News
Sports
Multimedia
Local Events
Classifieds
Obituaries
Weather
Online Features

Services

About Us
Contact Us
Promote Your Event
Subscriber Services
Online Forms
Rack Locations

woonsocketcall.com
Address: 154 Main Street
Woonsocket, RI 02895
Phone: 401-762-3000
Email: notices@woonsocketcall.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Log In Using Your Account

UroGen Pharma Ltd. - Ordinary Shares (NQ:URGN)

Press Releases about UroGen Pharma Ltd. - Ordinary Shares

Sections

Services